Key facts
- Synamics Therapeutics’s last known valuation is $1.4M (Jul 2024).
- It has raised $290K; the latest was Seed Round in Jul 2025.
- Notable investors include Plug and Play Tech Center, ARCH Venture Partners, Steen Riisgaard.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Synamics Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Synamics Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Synamics Therapeutics
Operator of a biotechnology company intended to develop cancer drugs. The company leverages artificial intelligence technology to develop novel therapies aimed at overcoming drug resistance in cancer, enabling patients to have access to oncology medicines.
- Sector
- Healthcare
- HQ
- Beverly Hills, CA, United States
- Founded
- 2023
- Website
- synamics.com/
- Ownership
- Privately Held (backing)
Synamics Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Synamics Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Synamics Therapeutics in its N-PORT filings yet. We sweep new filings monthly.